Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cretostimogene grenadenorepvec - CG Oncology

X
Drug Profile

Cretostimogene grenadenorepvec - CG Oncology

Alternative Names: CG-0070

Latest Information Update: 15 May 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cell Genesys; Genetic Therapy
  • Developer CG Oncolgy; Lepu Biopharma
  • Class Antineoplastics; Immunotherapies; Oncolytic viruses
  • Mechanism of Action Cell death stimulants; Granulocyte macrophage colony stimulating factor agonists; Immunologic cytotoxicity
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Bladder cancer
  • No development reported Solid tumours

Most Recent Events

  • 03 May 2024 CG Oncolgy announces intention to submit regulatory application for non muscular invasive Bladder cancer
  • 03 May 2024 Efficacy and adverse events data from the phase III BOND-003 trial in non-muscular invasive Bladder cancer (NMIBC) released by CG Oncolgy
  • 12 Feb 2024 H. Lee Moffitt Cancer Center and Research Institute initiates a phase Ib trial for Bladder cancer in USA (Intravesicular) (NCT06253845)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top